AI revolution in lung disease care: Brainomix and Boehringer Ingelheim forge game-changing partnership

Brainomix, a leader in artificial intelligence (AI) imaging solutions, has announced a partnership with the German pharmaceutical giant Boehringer Ingelheim. This collaboration aims to enhance the care of patients suffering from fibrosing lung disease in the United States through the innovative application of AI imaging analysis.

The partnership will focus on utilizing Brainomix’s FDA-cleared e-Lung software across leading US pulmonology centers and their networks. The initiative targets the integration of AI technology in routine CT scans to facilitate quicker diagnosis and better treatment accessibility for patients with pulmonary fibrosis—a chronic, progressive, and life-limiting lung condition. Typically, patients may face a diagnosis time of up to two years, during which the disease can significantly progress, drastically shortening life expectancy if untreated.

Brainomix’s e-Lung solution aims to transform this scenario by enabling the early identification of eligible patients for treatment, a task that poses considerable challenges even for expert clinicians. The partnership’s efforts are expected to generate real-world evidence supporting the use of e-Lung to optimize care pathways and enhance outcomes for patients with fibrosing lung disease.

Brainomix and Boehringer Ingelheim are transforming fibrosing lung disease care with groundbreaking AI imaging technology

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix, emphasized the urgent need for improved identification processes for patients with this condition. “This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease,” said Dr. Papadakis. He highlighted the potential of the e-Lung software to facilitate earlier access to specialist care and treatment, potentially slowing disease progression.

Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim, also shared his insights: “At Boehringer Ingelheim, we know how critical early and confident detection of progression is for people living with fibrosing lung disease. We believe that Brainomix 360 e-Lung has the potential to revolutionize the diagnostic landscape and thereby enable earlier treatment decisions at a pivotal stage of the patient’s journey.”

The announcement of this partnership coincides with Brainomix’s recent showcase of new studies at the American Thoracic Society Conference, which underscored the prognostic value of its lung imaging biomarkers. These studies reflect the company’s growing Life Sciences partnerships and academic collaborations, particularly in the lung disease sphere.

Brainomix, originally a spin-out from the University of Oxford, continues to expand its global presence, now operating in over 30 countries. The company is backed by leading healthtech investors and has already seen its AI-powered software solutions, including the Brainomix 360 stroke platform, clinically adopted in hundreds of hospitals worldwide.

This partnership represents a significant advancement in the field of medical AI, particularly in the treatment and management of fibrosing lung disease. By integrating AI into routine clinical workflows, Brainomix and Boehringer Ingelheim are setting new standards in the healthcare industry, potentially improving the quality of life for thousands of patients.